Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel monoclonal antibodies for the treatment and diagnosis of cancer. The company is pursuing multiple company and investigator-sponsored clinical programs with its lead immunotherapy candidate bavituximab including the SUNRISE Phase III trial in patients with second-line non-small cell lung cancer. Other indications include front-line non-small cell lung, liver, breast and rectal cancers as well as melanoma. The company is also investigating an imaging agent that represents a potential new approach to imaging cancer. Peregrine has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com) which provides development and biomanufacturing services for both Peregrine and outside customers.
Company Growth (employees)
Type
Public
HQ
Tustin, US
Founded
1981
Size (employees)
281 (est)+34%
Peregrine Pharmaceuticals was founded in 1981 and is headquartered in Tustin, US

Peregrine Pharmaceuticals Office Locations

Peregrine Pharmaceuticals has an office in Tustin
Tustin, US (HQ)
14282 Franklin Ave

Peregrine Pharmaceuticals Data and Metrics

Peregrine Pharmaceuticals Financial Metrics

Peregrine Pharmaceuticals's revenue was reported to be $44.7 m in FY, 2016 which is a 67% increase from the previous period.
USD

Revenue (FY, 2016)

44.7 m

Revenue growth (FY, 2015 - FY, 2016), %

67%

Net income (FY, 2016)

(55.7 m)

EBIT (FY, 2016)

(56.4 m)

Market capitalization (21-Jul-2017)

194.1 m
Peregrine Pharmaceuticals's current market capitalization is $194.1 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

22.4 m26.8 m44.7 m

Revenue growth, %

20%67%

R&D expense

59.5 m

General and administrative expense

18.6 m

Operating expense total

26.5 m39.3 m35 m

EBIT

(35.7 m)(50.5 m)(56.4 m)

EBIT margin, %

(159%)(189%)(126%)

Net Income

(35.4 m)(50.4 m)(55.7 m)
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

77.5 m68 m61.4 m

Inventories

5.5 m7.4 m16.2 m33.1 m

Current Assets

85.8 m80.5 m81.8 m

PP&E

2.4 m15.1 m24.3 m

Total Assets

90.5 m97.5 m109 m

Accounts Payable

2.4 m10.4 m8.4 m5.8 m

Current Liabilities

22.2 m37.3 m57.6 m

Additional Paid-in Capital

470.8 m512.5 m559.1 m

Retained Earnings

(403.3 m)(453.6 m)(509.3 m)

Total Equity

67.7 m59 m50.1 m

Financial Leverage

1.3 x1.7 x2.2 x
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(35.4 m)(50.4 m)(55.7 m)(28.2 m)

Depreciation and Amortization

986 k1 m1.5 m2.5 m

Inventories

(1.2 m)(1.8 m)(8.8 m)(16.9 m)

Accounts Payable

(391 k)3.3 m(3.5 m)(3.3 m)

Cash From Operating Activities

(28.3 m)(36 m)(39.6 m)(39.8 m)

Cash From Investing Activities

(2.5 m)(8.4 m)(8.8 m)(3 m)

Dividends Paid

(232 k)(3.4 m)(4.1 m)(4.3 m)

Cash From Financing Activities

73.1 m35 m41.8 m28.2 m

Interest Paid

6 k

Peregrine Pharmaceuticals Operating Metrics

FY, 2016

Phase 1/2

1

Peregrine Pharmaceuticals Market Value History

Peregrine Pharmaceuticals Revenue Breakdown

Peregrine Pharmaceuticals Company Life and Culture

You may also be interested in